C2orf28 antibody - C-terminal region (ARP36564_P050)
- Known as:
- C2orf28 (anti-) - C-terminal region (ARP36564_P050)
- Catalog number:
- arp36564_p050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- C2orf28 antibody - C-terminal region (ARP36564_P050)
Related genes to: C2orf28 antibody - C-terminal region (ARP36564_P050)
- Gene:
- ATRAID NIH gene
- Name:
- all-trans retinoic acid induced differentiation factor
- Previous symbol:
- C2orf28
- Synonyms:
- HSPC013, p18, APR3
- Chromosome:
- 2p23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-05-10
- Date modifiied:
- 2015-12-02
Related products to: C2orf28 antibody - C-terminal region (ARP36564_P050)
Related articles to: C2orf28 antibody - C-terminal region (ARP36564_P050)
- Gestational diabetes mellitus (GDM) is a common pregnancy complication with adverse maternal and fetal outcomes, yet its genetic basis is not fully understood. Previous genome-wide association studies (GWAS) have identified only a limited number of susceptibility loci, most of which overlap with genes for type 2 diabetes (T2D). - Source: PubMed
Publication date: 2026/04/23
Zhao WendiHu HongLi MinLiu LingPeng WeiChu Yijing - Liver fibrosis (LF), cirrhosis, and hepatocellular carcinoma (HCC) are strongly correlated and impose a heavy burden on the global healthcare system. Currently, there are no effective treatments, and thus we performed dual-omics analysis to identify new targets and regulatory mechanisms. - Source: PubMed
Publication date: 2025/12/15
Chen JianCao RonggeHe ZhiyuanLi ZifanHong YananRen ChuanzengWang YingWu JiazhaoLiu YongqingXia Honghai - Irritable bowel syndrome (IBS), a gastrointestinal motility disorder affecting millions of patients worldwide, has a substantial impact on healthcare economics and patient quality of life. However, fully satisfactory therapeutic options remain lacking. The identification of pathogenic proteins supported by causal genetic evidence enables the exploration of potential therapeutic targets for IBS. - Source: PubMed
Publication date: 2025/10/30
Li YitongJiao YaoWang MuyuanHu JiayanYuan YaliQu YingdiZhang WenjiYu YitongLu XinyuLiang ChengtaoLin ZhengdaoLi JunxiangMao TangyouXie Chune - Despite the development and application of numerous biomarkers and targeted therapeutic approaches for bladder cancer, substantial limitations and challenges persist in its early diagnosis and targeted treatment. As a result, there is an immediate necessity to discover novel biomarkers and develop new targeted drugs. In the present study the association between genes and bladder cancer was analyzed through Mendelian randomization (MR). Sensitivity analysis was conducted to evaluate the reliability of gene causality. Colocalization analysis was used to reduce confounding factors due to linkage disequilibrium and improve the accuracy of causal inference. Validation was performed using quantitative polymerase chain reaction (qPCR) in bladder cancer cell lines. A nomogram model was constructed, and drug sensitivity analysis and single-cell expression typing were conducted to predict survival, select potential therapeutic targets, and detect specific cell types with abundant expression. The results identified seven genes whose predicted levels were associated with bladder cancer risk in the MR analysis. Elevated levels of four genes and decreased levels of three genes were associated with low risk of bladder cancer. All- retinoic acid-induced differentiation factor (ATRAID) and tripartite motif containing 25 (TRIM25) showed colocalization with SNP.PP.H4 values >0.95, indicating a high likelihood of association with bladder cancer risk. Reverse transcription qPCR validation revealed low expression of ATRAID and TRIM25 in bladder cancer. ATRAID is primarily expressed in fibroblasts and smooth muscle cells, while TRIM25 is highly expressed in endothelial cells. Using clinical data from patients, a model based on ATRAID and TRIM25 demonstrated excellent predictive performance. Furthermore, drug analysis revealed that the expression of ATRAID and TRIM25 is closely associated with the sensitivity to various chemotherapy drugs. In the present study, ATRAID and TRIM25 were identified as two biomarkers linked to the risk of bladder cancer. These findings not only provide new insights into the etiology of bladder cancer but also identify novel targets for the development of biomarkers and therapeutic medications against the disease. - Source: PubMed
Publication date: 2025/10/06
Gao WenzhiLi YueFu ZhixinGao ZihuiGu YamingJia XiaopengJiang YuqingGuo Yuexian - Benign prostatic hyperplasia (BPH) is a widely observed disorder in older men, with substantial evidence indicating that cellular senescence serves a pivotal function in its progression. This investigation seeks to pinpoint cellular senescence-related genes causally connected with BPH and to examine their expression and regulatory networks across distinct prostate cells. - Source: PubMed
Wang YichuanZhou LiangLiu JiahaoZhou QingXiong WeiWang Long